A phase I study of axitinib (AG-013736) in combination with bevacizumab plus chemotherapy or chemotherapy alone in patients with metastatic colorectal cancer and other solid tumors

Annals of Oncology : Official Journal of the European Society for Medical Oncology
S SharmaR L Robles

Abstract

Axitinib and bevacizumab are targeted therapies against the vascular endothelial growth factor pathway. Patients with previously treated solid tumors received axitinib (starting dose 5 mg twice daily) combined with FOLFOX plus bevacizumab (1, 2, or 5 mg/kg, cohorts 1-3, respectively), FOLFIRI (cohort 4), or FOLFOX (cohort 5). Safety and pharmacokinetics were assessed. Thirty patients were enrolled (n = 16, 8, and 6 for cohorts 1-3, 4, and 5, respectively). Plasma concentrations and pharmacokinetic (PK) parameters were similar when drugs were administered alone and in various combinations. Most treatment-emergent adverse events (AEs) were mild to moderate and clinically manageable (most common: nausea, fatigue, diarrhea, anorexia, hypertension). Two of the four patients receiving axitinib with FOLFOX plus 5 mg/kg bevacizumab experienced dose-limiting toxicity (DLT) of inability to resume treatment for 14 days following treatment interruption (associated AE: hypertension); the maximum tolerated dose of bevacizumab in this combination was 2 mg/kg. No DLTs occurred with axitinib plus FOLFIRI or FOLFOX. Ten patients had RECIST-confirmed partial tumor responses (objective response rate: 33.3%). Axitinib is well tolerated in combinati...Continue Reading

References

Apr 1, 1989·Clinical Pharmacokinetics·R B Diasio, B E Harris
Feb 5, 2000·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·T AndréA de Gramont
Feb 7, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M S GordonD Adelman
Jun 4, 2004·The New England Journal of Medicine·Herbert HurwitzFairooz Kabbinavar
Dec 9, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Daniel J Hicklin, Lee M Ellis
Mar 23, 2005·Pharmacology & Therapeutics·Tony K L KiangThomas K H Chang
Jul 20, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Hope S RugoGeorge Wilding
Feb 16, 2006·Drug Discovery Today·Mohammad A TabriziLorin K Roskos
Jun 11, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Ezra E W CohenRoger B Cohen
Aug 2, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Nilofer S AzadElise C Kohn
Sep 10, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Marc C Chamberlain
Nov 18, 2008·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Dana D Hu-LoweSteve L Bender
Jul 15, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Joan H SchillerJoachim von Pawel
Aug 5, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Brian I RiniJanice P Dutcher

❮ Previous
Next ❯

Citations

Jun 1, 2011·Cancer Chemotherapy and Pharmacology·Jeffrey R InfanteHoward A Burris
Oct 31, 2009·Targeted Oncology·Ronan J Kelly, Olivier Rixe
Feb 15, 2011·Current Oncology Reports·Pankaj Bhargava, Murray O Robinson
Aug 22, 2013·World Journal of Gastroenterology : WJG·Efstathios T Pavlidis, Theodoros E Pavlidis
May 17, 2013·Clinical Pharmacokinetics·Ying ChenYazdi K Pithavala
Apr 30, 2013·The Journal of Biological Chemistry·Franziska StehleBarbara Seliger
Jun 4, 2015·Expert Opinion on Drug Discovery·Yousef ZakhariaOlivier Rixe
Feb 27, 2015·International Journal of Cancer. Journal International Du Cancer·Andreas K A GaumannGeorg Breier
Jul 24, 2015·Clinical Pharmacokinetics·Beatrix WulkersdorferMonika Schmid
Jul 7, 2011·Clinical Colorectal Cancer·Vikram K JainDavid Cunningham
Aug 27, 2013·Seminars in Oncology·Alain RavaudJoaquim Bellmunt
Oct 12, 2017·European Journal of Drug Metabolism and Pharmacokinetics·Matteo MorottiSimon Lord
Apr 9, 2010·Current Opinion in Oncology·Joleen Hubbard, Axel Grothey
Jan 29, 2013·Cancer Chemotherapy and Pharmacology·Jane KendrewJuliane M Jürgensmeier
Oct 15, 2010·Expert Review of Anticancer Therapy·Robert GoldsteinJames Larkin
Jun 28, 2018·Bulletin of Mathematical Biology·Yixuan HeDorothy I Wallace
May 10, 2013·Expert Review of Clinical Pharmacology·Safi Shahda, Muhammad Wasif Saif
May 31, 2012·Cancer Chemotherapy and Pharmacology·Yazdi K PithavalaMichael A Tortorici
Jun 18, 2011·Drugs in R&D·Bernard Escudier, Martin Gore
May 2, 2012·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Victor Moreno GarciaStan B Kaye
Jan 14, 2022·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Juan TamargoEva Delpón

❮ Previous
Next ❯

Related Concepts

Related Feeds

Angiogenesis Inhibitors to Treat Cancer

Cancer treatments including angiogenesis inhibitors prevent tumor cells from receiving nutrients and oxygen. Here is the latest research on angiogenesis inhibitors for the treatment of cancer.

Arterial-Venous in Development & Disease

Arterial-venous development may play a crucial role in cardiovascular diseases. Here is the latest research.

Anorexia Nervosa

Anorexia nervosa (AN) is a psychiatric condition characterized by severe weight loss and secondary problems associated with malnutrition. Here is the latest research on AN.

© 2022 Meta ULC. All rights reserved